Significance of nicotine and nicotinic acetylcholine receptors in Parkinson's disease.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and epidemiological associations without primary data or systematic synthesis
PubMed 40191787 · doi:10.3389/fnagi.2025.1535310
What was done
This narrative review synthesized literature on the pathological mechanisms of Parkinson's disease, the epidemiological link between tobacco smoking and reduced disease risk, and the molecular interactions between nicotine and nicotinic acetylcholine receptors (nAChRs) regarding neuroprotection.
What was found
The abstract reports no primary quantitative data or effect sizes. It describes the inverse relationship between smoking and Parkinson's disease risk and highlights that nicotine interactions with diverse nAChR subtypes mediate neuroprotective mechanisms against dopaminergic neuron degeneration and alpha-synuclein pathology.
Why it matters
Clarifying the molecular pathways of nAChR activation helps translate the observed inverse epidemiological association between smoking and Parkinson's disease into targeted, non-toxic therapeutic candidates.
Limits
As a narrative review, it presents no original empirical data, quantitative meta-analysis, or systematic search methodology. The abstract does not report specific effect sizes, nAChR subtype affinities, or clinical trial outcomes of nicotine-based interventions.
Cited by
- partial Nicotine exerts protective effects against Parkinson's disease and Alzheimer's disease.